Skip to content
Search

Latest Stories

Submit Guest Post

Lord Swraj Paul's group company completes capital investment in the US

A Caparo group company has completed major capital investment projects at its two largest tubular facilities in Elkhart and Trenton in the US.

The Bull Moose Tube company(BMT), a Caparo Bull Moose subsidiary, has said that the upgrades will enhance product quality, increase production efficiency and reliability, and add operational flexibility.


Caparo group is a diversified global association of businesses, with interests in the design, manufacture, marketing and distribution of value-added steel and niche engineering products.

It was founded in 1968 by Indian-born British Industrialist Lord Swraj Paul.

The new projects involved leading edge upgrades to the drive and automation control system, installation of a new induction unit, upgrades to the sizing section of the mill with state-of-the-art quality assurance capabilities, and upgraded cutoff quality and length accuracy, a statement from the company said.

"Our continued focused investments, capable leadership and skilled workforce is a winning combination that will solidify our position as a leading manufacturer and supplier of premier pipe & tube products in North America," said Lord Paul.

Tom Modrowski, president and CEO of BMT, said: "The investments in our facilities are part of our strategy to build a sustainable portfolio of assets across the Company's operational footprint. It reflects our enduring commitment to innovation, high quality, and superior customer service."

The BMT is based in Chesterfield, Missouri and operates from seven plants – six in the US and one in Canada.

It offers one of the largest ranges of welded steel tubing in North America.

Add EasternEye As Your Trusted Source
preferred source on google news

More For You

Hair Loss risks

Popular GLP-1 weight loss drugs are facing fresh scrutiny over reports of hair loss.

iStock

Hair loss risk up by 68 per cent? New study puts GLP-1 drugs under the spotlight

  • Researchers found GLP-1 drugs were associated with up to a 68 per cent higher risk of hair loss than some other diabetes medicines.
  • UK regulators have received more than 1,200 reports of hair loss linked to semaglutide and tirzepatide since last year.
  • Experts say rapid weight loss may be the most likely explanation, but further research is needed.

Popular GLP-1 weight loss drugs such as Mounjaro, Ozempic and Wegovy are under fresh scrutiny after a major study found they may be linked to a higher risk of hair loss. The findings add to a growing number of reports already being reviewed by health regulators in both the UK and the US, although researchers say more evidence is needed before any direct link can be confirmed.

The study, published in the British Medical Journal (BMJ), analysed health records from around 50,000 adults and compared people taking GLP-1 receptor agonists with those using other medicines to manage type 2 diabetes. Researchers found that people using GLP-1 drugs had a 37 per cent higher risk of developing alopecia than those taking SGLT-2 inhibitors, while the risk was 68 per cent higher compared with people using DPP-4 inhibitors.

Keep ReadingShow less